Abstract The ArteraAI Prostate Test (ArteraAI Inc. ) is the first predictive biomarker for benefit of adding short-term androgen deprivation therapy (ADT) to radiotherapy for intermediate-risk prostate cancer. We evaluated the cost-effectiveness of ArteraAI to guide short-term ADT with a Markov model simulating 15-year outcomes for 71-year-old patients with intermediate-risk prostate cancer receiving radiotherapy using NRG/RTOG 9408 data on which ArteraAI was validated. Three strategies were compared: 1) all patients receive ADT (ADT-for-all), 2) only patients with unfavorable intermediate-risk prostate cancer receive ADT (National Comprehensive Cancer Network NCCN), and 3) only ArteraAI-positive patients receive ADT (ArteraAI). Costs and utilities obtained from Medicare claims and published literature were used to calculate incremental cost-effectiveness ratios (ICERs). A willingness-to-pay threshold of 100, 000/QALY was chosen. The ADT-for-all strategy was dominated by the NCCN strategy. Compared with the NCCN strategy, the ArteraAI strategy lowered costs by 12, 296 and improved effectiveness by 0. 01 QALYs, and thus was dominant.
Courtney et al. (Wed,) studied this question.